tbuckley/cabot-search huggingface dataset:
The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms
Authors: Feng Chen, Yanting Chen, Yongxiang Wang, Qiongwei Ke, Lili Cui
Journal: Translational Neurodegeneration (2022)

Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a life-threatening disease, especially in elderly individuals and those with comorbidities. The predominant clinical manifestation of COVID-19 is respiratory dysfunction, while neurological presentations are increasingly being recognized. SARS-CoV-2 invades host cells primarily via attachment of the spike protein to the angiotensin-converting enzyme 2 (ACE2) receptor expressed on cell membranes. Patients with Alzheimer's disease (AD) are more susceptible to SARS-CoV-2 infection and prone to severe clinical outcomes. Recent studies have revealed some common risk factors for AD and COVID-19. An understanding of the association between COVID-19 and AD and the potential related mechanisms may lead to the development of novel approaches to treating both diseases. In the present review, we first summarize the mechanisms by which SARS-CoV-2 invades the central nervous system (CNS) and then discuss the associations and potential shared key factors between COVID-19 and AD, with a focus on the ACE2 receptor, apolipoprotein E (APOE) genotype, age, and neuroinflammation.
Haploidentical transplantation with post‐transplant cyclophosphamide versus single cord blood transplantation for myelodysplastic syndrome: A retrospective study from the Adult Myelodysplastic Syndrome Working Group of the Japanese Society for Transplantation and Cellular Therapy (<scp>JSTCT</scp>)
Authors: Takaaki Konuma, Yoshimitsu Shimomura, Ken Ishiyama, Takahide Ara, Hirohisa Nakamae, Nobuhiro Hiramoto, Tetsuya Eto, Yumiko Maruyama, Koji Nagafuji, Jun Ishikawa, Naoyuki Uchida, Masatsugu Tanaka, Makoto Onizuka, Yasunori Ueda, Naoyuki Anzai, Takafumi Kimura, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta
Journal: American Journal of Hematology (2022)
Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial
Authors: Birgitte V. Offersen, Jan Alsner, Hanne M. Nielsen, Erik H. Jakobsen, Mette H. Nielsen, Lars Stenbygaard, Anders N. Pedersen, Mette S. Thomsen, Esben Yates, Martin Berg, Ebbe L. Lorenzen, Ingelise Jensen, Mirjana Josipovic, Maj-Britt Jensen, Jens Overgaard
Journal: Journal of Clinical Oncology (2022)

On the basis of low risk of local recurrence in elderly patients with breast cancer after conservative surgery followed by whole breast irradiation (WBI), the Danish Breast Cancer Group initiated the noninferiority external-beam partial breast irradiation (PBI) trial (ClinicalTrials.gov identifier: NCT00892814). We hypothesized that PBI was noninferior to WBI regarding breast induration.Patients operated with breast conservation for relatively low-risk breast cancer were randomly assigned to WBI versus PBI, and all had 40 Gy/15 fractions. The primary end point was 3-year grade 2-3 breast induration.In total, 865 evaluable patients (434 WBI and 431 PBI) were enrolled between 2009 and 2016. Median follow-up was 5.0 years (morbidity) and 7.6 years (locoregional recurrence). The 3-year rate of induration was 9.7% for WBI and 5.1% for PBI (P = .014). Large breast size was significantly associated with induration with a 3-year incidence of 13% (WBI) and 6% (PBI) for large-breasted patients versus 6% (WBI) and 5% (PBI) for small-breasted patients. PBI showed no increased risk of dyspigmentation, telangiectasia, edema, or pain, and patient satisfaction was high. Letrozole and smoking did not increase the risk of radiation-associated morbidity. Sixteen patients had a locoregional recurrence (six WBI and 10 PBI; P = .28), 20 patients had a contralateral breast cancer, and eight patients had distant failure (five WBI and three PBI). A nonbreast second cancer was detected in 73 patients (8.4%), and there was no difference between groups.External-beam PBI for patients with low-risk breast cancer was noninferior to WBI in terms of breast induration. Large breast size was a risk factor for radiation-associated induration. Few recurrences were detected and unrelated to PBI.
Characterization of Immune-Related Alternative Polyadenylation Events in Cancer Immunotherapy
Authors: Gaoyang Wang, Zuozhong Xie, Juan Su, Meishan Chen, Yanhua Du, Qian Gao, Guanxiong Zhang, Hailun Zhang, Xiang Chen, Hong Liu, Leng Han, Youqiong Ye
Journal: Cancer Research (2022)

Abstract Alternative polyadenylation (APA) is an important posttranscriptional modification commonly involved in tumor development. However, the functional roles of APA in tumor immunity remain largely unknown. Here, we performed an in-depth analysis of the 3′UTR usage of protein-coding genes and tumor immune response in 10,303 tumor samples across 31 cancer types to develop the immune-related APA event (ImmAPA) score pipeline, an integrated algorithm to characterize the regulatory landscape of APA events in cancer immunity–related pathways. Tumor-specific ImmAPAs that strongly correlate with immune cell infiltration and immune checkpoint blockade (ICB) treatment–related biomarkers were identified. Among these ImmAPAs, the top-ranking COL1A1 3′UTR usage was strongly associated with worse prognosis and tumor immune evasion. Furthermore, a machine learning approach to construct an ICB-related ImmAPA score model predicted immunotherapy efficacy. Overall, the characterization of immune-related APA that corresponds to tumor progression and tumor immunity highlights the clinical utility of APA events as potential biomarkers in cancer immunotherapy. Significance: Elucidation of the landscape of immune-related alternative polyadenylation in cancer identifies alternative polyadenylation events that may play a role in immune modulation and immunotherapy efficacy.
EP07.01-021 Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy
Authors: M. Occhipinti, A. Tacchetto, T. Beninato, C.C. Pircher, L. Mazzeo, S. Manglaviti, A. De Toma, G. Galli, A. Prelaj, R. Ferrara, C. Proto, G. Lo Russo, M. Ganzinelli, A. Di Nucci, I. Grande, A. Rinaldi, M. Platania, M.C. Garassino, P. Marchetti, F.M. de Braud, M. Brambilla
Journal: Journal of Thoracic Oncology (2022)
EP08.02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors
Authors: M. Villalona Calero, A. Patnaik, R. Maki, B. O'Neil, J. Abbruzzese, I. Dagogo-Jack, S. Devarakonda, S. Wahlroos, C.-C. Lin, Y. Fujiwara, A. Terbuch, S. Postel-Vinay, M.-E. Goebeler, A. Addeo, H. Prenen, T. Arkenau, A. Sacher, C. Liu, W. Kormany, J. Ahnert
Journal: Journal of Thoracic Oncology (2022)
EP08.02-158 Final Analyses of ALTER-L018: A Randomized Phase II Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-line Therapy for EGFR-negative NSCLC
Authors: L. Wu, Z. Wu, Z. Xiao, Z. Ma, J. Weng, Y. Chen, Y. Cao, P. Cao, M. Xiao, H. Zhang, H. Duan, Q. Wang, J. Li, Y. Xu, X. Pu, K. Li
Journal: Journal of Thoracic Oncology (2022)
EP08.02-144 The Impact of CNS Recurrence on Post-recurrence Survival in Patients with EGFR-mutation-positive Non-small-cell Lung Cancer
Authors: T. Okamoto, T. Takenaka, K. Yamazaki, M. Hamatake, N. Miura, M. Takenoyama, T. Kometani, H. Ueda, H. Kouso, T. Yano
Journal: Journal of Thoracic Oncology (2022)
EP05.02-021 An Updated Analysis of Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable NSCLC
Authors: Y. Zhang, L. Zeng, X. Zhang, Y. Zhou, B. Zhang, L. Guo, W. Jiang, Y. Xiong, H. Yang, L. Liu, T. Jiang, C. Zhou, N. Yang
Journal: Journal of Thoracic Oncology (2022)
EP08.02-128 Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial
Authors: H. Park, J.S. Jung, Y.M. Kim, Y. Kang, W. Ji, J.C. Lee, C.-M. Choi
Journal: Journal of Thoracic Oncology (2022)
EP16.01-016 Tumor Treating Fields (TTFields) Application Promotes a Pro-inflammatory Phenotype in Macrophages
Authors: Y. Barsheshet, B. Brant, T. Voloshin, A. Volodin, L. Koren, B. Koltun, A. Klein-Goldberg, E. Zemer-Tov, T. Kan, R. Paz, M. Giladi, U. Weinberg, Y. Palti
Journal: Journal of Thoracic Oncology (2022)
P2.08-07 The Campaign to End Lung Cancer Stigma: The ACS National Lung Cancer Roundtable Efforts to Confront and Extinguish Lung Cancer Stigma
Authors: J. Studts, L. Carter, J. Feldman, D. Donaldson, J. Pantelas, J. Ostroff, B. Stiles, E. Scharnetzki, R. Smith, E. Kazernooni, L. Rosenthal, K. Durden, K. Burn, None A. Campaign to End Lung Cancer Stigma
Journal: Journal of Thoracic Oncology (2022)
EP14.01-021 Anlotinib Plus Irinotecan or Docetaxel in Small-Cell Lung Cancer (SCLC) Relapsed within Six Months: a Single-Arm Phase II Study
Authors: B. Xia, M. Zhang, X. Chen, H. Jiang, J. Wang, J. Ye, S. Ma
Journal: Journal of Thoracic Oncology (2022)
EP10.01-008 Examining Social Determinants of Health Among Newly Diagnosed Lung Cancer Patients Contacted for Early Specialist Palliative Care Consultation
Authors: S. King, S. Ahmed, L. Shirt, V. Slobogian, C. Vig, L. Barbera, E. Kurien, M. Santana, A. Pabani, P. Biondo, A. Sinnarajah, J. Simon, D. Hao
Journal: Journal of Thoracic Oncology (2022)
EP08.02-118 TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors
Authors: N. Misako, S. Sugawara, C.-M. Choi, T. Okamoto, N. Yanagitani, K. Nosaki, T. Takahashi, Y. Fujiwara, H. Hayashi, J. Khoury, J. Nieva, A.E. Gabayan, L.E. Raez, H. Chen, A. Dimou, N. Pennell, G. Liu, S.-H.I. Ou, T. Seto, Y. Ohe
Journal: Journal of Thoracic Oncology (2022)
EP08.04-005 Phase II Study of Ramucirumab and Docetaxel for NSCLC Patients with Malignant Pleural Effusion
Authors: S. Takemoto, M. Fukuda, H. Senju, K. Nakatomi, N. Sugasaki, R. Ogata, H. Tomono, T. Suyama, M. Shimada, K. Akagi, F. Hayashi, H. Gyotoku, H. Yamaguchi, S. Nagashima, H. Soda, A. Kinoshita, H. Mukae
Journal: Journal of Thoracic Oncology (2022)
P1.15-09 First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.
Authors: M. Provencio-pulla, A.L. Ortega, J. Coves, F. Franco, R. Marsé, M. Dómine, M. Guirado, E. Carcereny, N. Fernández, E. Martinez, R. Blanco, L. León, J.M. Sánchez, I. Sullivan, M. Cobo, A. Sánchez, B. Massutí
Journal: Journal of Thoracic Oncology (2022)
EP02.03-019 T3 Non Small Cell Lung Cancer with Satellite Nodules: A Multicentric Analysis.
Authors: P. Bertoglio, M. La Porta, V. Aprile, S.N. Forti Parri, T. Ferrarello, E. Garelli, D. Bacchin, F. Ambrosi, B. Bonfanti, K. Kawamukai, J. Brandolini, M. Fiorentino, M. Lucchi, P. Solli
Journal: Journal of Thoracic Oncology (2022)
EP08.02-082 Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
Authors: J.Y. Lee, V. Mai, M. Garcia, S. Cheng, K. Khan, K. Balaratnam, A. Thakral, M.C. Brown, L. Zhan, L. Corke, N. Leighl, F.A. Shepherd, P. Bradbury, A. Sacher, G. Liu
Journal: Journal of Thoracic Oncology (2022)
EP08.03-006 Survival After Radical Treatment of Oligometastatic Non-small Cell Lung Cancer: A Multicenter Analysis
Authors: R.S. Werner, K. Furrer, C. Shen, Y. Wang, A. Curioni-Fontecedro, M. Guckenberger, A. Matter, V.W.T. Fang, I. Opitz
Journal: Journal of Thoracic Oncology (2022)
EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
Authors: M. Scheffler, M. Dugan, M.M. Saleh, S. Koleczko, J. Brägelmann, C. Arolt, L. Nogova, R. Riedel, S. Michels, A. Eisert, R. Fischer, H. Scharpenseel, J.-P. Weber, A.H. Scheel, S. Merkelbach-Bruse, R. Büttner, F. Lafleur, R. Wild, L. Catanzariti, A.M. Hillmer, J. Wolf
Journal: Journal of Thoracic Oncology (2022)
P2.14-01 Clinical Utility of Reflex to Tissue-based Comprehensive Genomic Profiling (CGP) After Negative Liquid Biopsy (LBx) in NSCLC
Authors: H. Husain, R.W. Madison, J. Haberberger, C. Cho-Phan, J. Snider, T.D. Snow, R.S.P. Huang, G. Li, K. Tolba, A.B. Schrock, R. Graf, G.R. Oxnard
Journal: Journal of Thoracic Oncology (2022)
EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
Authors: M. Glaser, C. von Levetzow, S. Michels, L. Nogova, M. Katzenmeier, C. Wömpner, J. Schmitz, E. Bitter, I. Terjung, E. Passmann, D. Schaufler, A. Eisert, R. Fischer, R. Riedel, J.-P. Weber, S. Hahne, S. Merkelbach-Bruse, R. Büttner, J. Wolf, M. Scheffler
Journal: Journal of Thoracic Oncology (2022)
EP02.03-022 Evolution of Lung Cancer Resection Quality: A Prospective Staggered Implementation Quality Improvement Study
Authors: O. Akinbobola, N. Faris, M. Smeltzer, M. Ray, C. Fehnel, A. Pacheco, A. Saulsberry, K. Dortch, H.L. Wiggins, D. Talton, R. Eubanks, D.R. Stevenson, G. Valaulikar, H. Patel, B. Wolf, A. Koury, P. Levy, T. Ng, T. Robbins, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2022)
EP08.02-155 The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
Authors: Y.H. Huang, K.-H. Hsu, J.-S. Tseng, K.-C. Chen, G.-C. Chang, T.-Y. Yang
Journal: Journal of Thoracic Oncology (2022)
EP08.02-126 The MOMENT Disease Registry of Patients with Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
Authors: P. Christopoulos, W.T. Iams, D. Oksen, S.H. Mahmoudpour, T. Thia, G. Otto, M. Thomas
Journal: Journal of Thoracic Oncology (2022)
EP08.02-136 Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer
Authors: J. Shen, J. Huang, X. Li, B. Xia, B. Wang, S. Yang, K. Wu, M. Zhang, J. Wang, P. Zhao, X. Chen, S. Ma
Journal: Journal of Thoracic Oncology (2022)
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer
Authors: G. Mazzaschi, L. Moron Dalla Tor, G. Milanese, M. Balbi, D. Tognazzi, B. Lorusso, M. Verzè, M. Pluchino, R. Minari, L. Leo, R.E. Ledda, P. Bordi, A. Leonetti, S. Buti, G. Roti, F. Quaini, N. Sverzellati, M. Tiseo
Journal: Journal of Thoracic Oncology (2022)
EP08.02-019 Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Authors: A. Spira, D.R. Spigel, R. Camidge, A.J. de Langen, T.M. Kim, K. Goto, Y. Elamin, E. Shum, K.L. Reckamp, J. Rotow, S. Goldberg, S. Gadgeel, T.A. Leal, F. Albayya, S. Fitzpatrick, M. Louie-Gao, J. Parepally, A. Zalutskaya, H. Yu
Journal: Journal of Thoracic Oncology (2022)
EP07.01-003 Metadata-Oriented Data Engineering Approach for Integration of Medical Data: A Pilot Study
Authors: Y. Kahya, K.C. Yilmaz, F. Gorguner, G. Kocaman, B.M. Yenigun, C. Yuksel, A.E. Yilmaz, A. Kayi Cangir
Journal: Journal of Thoracic Oncology (2022)
P1.16-02 Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale
Authors: L. Mezquita, M. Riudavets, M. Garcia de Herreros, E. Auclin, M. Dorta, V. Albarran, M. Aldea, C. Naltet, M. Grecea, P. Martin-Romano, L.L. Lacroix, C. Nicotra, A. Arcocha, A. Gazzah, C. Pipinikas, C. Morris, K. Howarth, C. Teixidó, R. Reyes, N. Viñolas, C. Massard, F. Barlesi, D. Planchard, B. Besse
Journal: Journal of Thoracic Oncology (2022)
EP08.02-111 RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial
Authors: M.L. Johnson, R. Langdon, D. Ellison, A. Spira, H. Amin, M. Castine, D. Daniel, T. Larson, S. Sohoni, Y.-C. Chen, J. Hayes, L. Yang, S. Masciari, X. Wang, S. Toya
Journal: Journal of Thoracic Oncology (2022)
EP08.01-029 NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
Authors: E. Nadal, A. Cantero, A.L. Ortega, M. Dómine, A. Barba, A. Blasco, J. García, J. Mosquera, S. Vázquez, D. Rodríguez, R. López-Castro, O. Juan-Vidal, A. Sánchez, L. Paz-Ares, A. Hernández, P. Iranzo, P. Diz, M. Provencio, M. Simó, V. Navarro, J. Bruna
Journal: Journal of Thoracic Oncology (2022)
EP08.02-025 Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial
Authors: B.C. Cho, J.-Y. Han, K.H. Lee, Y.-G. Lee, D.-W. Kim, Y.J. Min, S.-W. Kim, E.K. Cho, J.-H. Kim, G.-W. Lee, S.S. Lee, N.M. Lee, H.W. Jang, M.-J. Ahn
Journal: Journal of Thoracic Oncology (2022)
EP08.02-097 Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina
Authors: L. Basbus, F. Tsou, V. Bluthgen, N. Castagneris, M. Rizzo, Y. Ferreira, D. Enrico, A.L. Antivero, C. Puparelli, M. Spotti, C. Martin, L. Lupinacci, J.N. Minatta
Journal: Journal of Thoracic Oncology (2022)
EP08.02-024 Research Efforts in Systemic Therapy of Lung Cancer With Brain Metastasis From 2015-21: A clinicaltrial.gov Registry Analysis
Authors: B.K. Venugopal, S. Kakumanu, A. Dubey, B. Bashir, R. Koul, S. Rathod
Journal: Journal of Thoracic Oncology (2022)
EP08.01-045 The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival
Authors: J.T. Wu, J. La, S. Han, M. Das, M. Glover, M. Scobie, M. Brophy, N. Do, S. Ahmed, N. Fillmore, M. Kelley
Journal: Journal of Thoracic Oncology (2022)
EP08.02-052 Safety and Efficacy of Dabrafenib Plus Trametinib in Chinese Patients With BRAF V600E- Mutation Positive Metastatic NSCLC
Authors: Y. Fan, Z. Jianying, Z. Yuanyuan, Y. Yan, Y. Nong, L. Juan, W. Jialei, Z. Jun, W. Zhehai, C. Jun, T. Zhu, H. Li, Z. Li
Journal: Journal of Thoracic Oncology (2022)
EP02.03-012 Peri-operative and Oncologic Outcomes after Robotic-Assisted Segmentectomy at a NCI-designated Cancer Center
Authors: J.J.A. Baldonado, A. Aboukheir, E.I.Q. Villanueva, T. Draeger, J. Tew, J. Garrett, C. Moodie, J.P. Fontaine, E.M. Toloza
Journal: Journal of Thoracic Oncology (2022)
EP05.01-013 Increased C-reactive Protein after Chemoradiotherapy and Immunotherapy in Locally Advanced Non-small Lung Cancer Indicates Worse Survival
Authors: K. Stanic, M. Vrankar, J. But-Hadžić, S. Jelerčič, A.L. Vodušek, E. Ćirić
Journal: Journal of Thoracic Oncology (2022)
EP08.02-017 Time on Treatment for Patients Treated With Anti-EGFR Tyrosine Kinase Therapy for Metastatic NSCLC: Real-World Experience Data
Authors: L. Apter, S. Sharman Moser, M. Wollner, G. Chodick, N. Siegelmann-Danieli
Journal: Journal of Thoracic Oncology (2022)
EP02.04-005 Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC
Authors: J.M. Lee, B. Sepesi, E.M. Toloza, J. Lin, H.I. Pass, B.E. Johnson, J.V. Heymach, M.L. Johnson, B. Ding, K. Schulze, Q. Zhu, C. Ngiam, E. Brandão, I. Bara, J. Chaft
Journal: Journal of Thoracic Oncology (2022)
P2.14-03 Restored Ubiquitination and Degradation of Exon 14 Skipped MET with Proteolysis Targeting Chimeras
Authors: A. Mansfield, J. Reddy Mallareddy, L. Yang, W.-H. Lin, R. Feathers, J. Ayers-Ringler, E. Tolosa, S. Kizhake, S. Kubica, L. Boghean, S. Alvarez, M.J. Naldrett, S. Singh, S. Rana, M. Zahid, J. Smadbeck, S.H. Johnson, F. Harris, S. Sotiriou, G. Karagouga, A. McCune, J. Schaefer-Klein, A. Quiñones-Hinojosa, A. Roden, F. Kosari, J. Cheville, G. Vasmatzis, P. Anastasiadis, M. Borad, A. Natarajan
Journal: Journal of Thoracic Oncology (2022)
EP08.02-013 Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC
Authors: A. Gibson, M. Dean, A.J. Elegbede, A. Pabani, G.J. Bebb, W.Y. Cheung
Journal: Journal of Thoracic Oncology (2022)
EP08.01-061 A Pilot Study of Avelumab and SABR in Non-Responding and Progressing NSCLC Patients Previously Treated with a Checkpoint Inhibitor
Authors: M.E. Daly, A. Monjazeb, S. Lim, L. Qi, Z. Li, J. Riess, T. Li, E. Moore, K. Kelly
Journal: Journal of Thoracic Oncology (2022)
P1.16-04 Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors
Authors: N. Reinmuth, D. Reznick, S.Y. Liu, M.C. Garassino, N. Girard, F. De Marinis, S.F. Mekan, R. Patel, M. Ding, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2022)
EP05.02-002 Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?
Authors: B. Tavara, M.L. Garrido, Z. Rodríguez, M. Rojas, L. López, S. Medina, C. Ponte, A. Lopez, E. Sanchez, M. Pedraza, P. Viñals, M. López, D. Alonso, A. Rodríguez, E. Davila, C. Castañon, L.M. De Sande, B. Nieto, M.E. Vallejo Pascual, J.d.l.R. Rodríguez, A. Garcia Palomo, P. Diz Taín
Journal: Journal of Thoracic Oncology (2022)
P2.10-01 Transcriptional Diversity of Emerging Cell Populations in Refractory Small Cell Lung Cancer Biopsies and Xenografts
Authors: C.A. Stewart, Y. Xi, R. Wang, K. Ramkumar, V.Y. Novegil, M. Frumovitz, J. Wang, L.A. Byers, C.M. Gay
Journal: Journal of Thoracic Oncology (2022)
EP05.03-006 Real-World Treatment Pathways In Stage III Non-Small Cell Lung Cancer in Portugal (PICTuRE): An Interim Analysis Of Surgical Patients
Authors: M.E. Teixeira, G. Fernandes, L. Ferreira, F. Estevinho, J.A. Lopes, A. Araújo, M.M. Figueiredo, L. Barradas, M. Lopes, U. Brito, A. Barroso, C. Camacho, B. Parente, M. Felizardo, A. Meleiro, M. Bernardo, C. Antunes, F. Bernardo, S. Figueiredo
Journal: Journal of Thoracic Oncology (2022)
EP07.02-004 Endogenous Retrovirus Expression and Type I Interferon Signaling in Human Mesothelioma
Authors: S. Sun, W. Qi, M. Ronner, A. Hariharan, M. Wipplinger, I. Opitz, H. Rehrauer, E. Felley-Bosco
Journal: Journal of Thoracic Oncology (2022)
EP08.01-093 ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer
Authors: L. Wu, B. Chen, J. Wang, X. Pu, J. Li, Q. Wang, L. Liu, Y. Xu, L. Xu, Y. Kong, K. Li, F. Xu
Journal: Journal of Thoracic Oncology (2022)
EP08.02-069 A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases
Authors: None s. Huang, None l. Li, None n. Yan, None h. Zhang, None s. Guo, None q. Guo, None d. Geng, None x. Li
Journal: Journal of Thoracic Oncology (2022)
EP08.02-101 Real-world Data from KRAS-mutant Advanced NSCLC: the ATLAS Multicenter Cohort Study
Authors: M. Bungaro, E. Garbo, F. Jacobs, M.L. Reale, F. Passiglia, M. Tiseo, C. Genova, D. Galetta, U. Malapelle, G. Troncone, S. Novello
Journal: Journal of Thoracic Oncology (2022)
EP02.03-018 Intermittent Chest Tube Clamping Shortens Chest Tube Duration After Lung Cancer Surgery: An Open-label, Randomized Controlled Trial
Authors: Y. Wang, Y. Pei, C. Lv, Y. Wang, J. Wang, D. Zhao, X. Li, Y. Yang, S. Yan, N. Wu
Journal: Journal of Thoracic Oncology (2022)
EP07.03-003 First Line Combination of Toripalimab and Chemotherapy in Advanced Thymic Carcinoma: A Single-Center, Prospective, Single-Arm, Phase II Trial
Authors: X. Hu, Y. Feng, H. Zhu, J. Lu, Y. Liu, P. Xing, H. Wang
Journal: Journal of Thoracic Oncology (2022)
EP05.01-021 Radiation Dose to Cardiac Substructures and the Incidence of Cardiac Events in Patients with Stage III NSCLC Receiving CCRT
Authors: M.X. Welliver, A. Goyal, X. Mo, S. Dick, G. Ma, J. Bazan, J. Brownstein, K. Haglund, T. Willimas, D. DiCostanzo, J. Grecula, D. Addison, E. Miller
Journal: Journal of Thoracic Oncology (2022)
EP08.02-072 The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs
Authors: A. Szpechcinski, M. Bryl, E. Wojda, G. Czyzewicz, D. Swiniuch, M. Szwiec, R. Ramlau, P. Sliwinski, A. Barinow-Wojewodzki, J. Chorostowska-Wynimko
Journal: Journal of Thoracic Oncology (2022)
EP07.03-004 Efficacy of Thoracic Radiotherapy for Local Progression in Advanced Thymic Carcinoma
Authors: M. Uematsu, Y. Goto, M. Torasawa, Y. Matsumoto, K. Masuda, Y. Shinno, Y. Okuma, T. Yoshida, H. Horinouchi, N. Yamamoto, Y. Ohe
Journal: Journal of Thoracic Oncology (2022)